

Edgar Filing: DOR BIOPHARMA INC - Form 8-K

DOR BIOPHARMA INC
Form 8-K
March 15, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 15, 2004

DOR BIOPHARMA, INC

(Exact name of registrant as specified in its charter)

DELAWARE ----- (State or other jurisdiction of incorporation)	1-14778 ----- (Commission File Number)	41-1505029 ----- (IRS Employer Identification No.)
--	---	---

1691 MICHIGAN, SUITE 435, MIAMI, FL ----- (Address of principal executive offices)	33139 ----- (Zip Code)
--	------------------------------

Registrant's telephone number, including area code (305) 534-3383

NOT APPLICABLE

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

We have completed our sale of securities in a private placement to institutional investors with gross proceeds of \$3.25 million. On March 15, 2004, we issued a press release with respect thereto, which is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference

Exhibits

99.1 Press Release of DOR BioPharma, Inc regarding the Private

Edgar Filing: DOR BIOPHARMA INC - Form 8-K

Placement Financing

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DOR BioPharma, Inc.

Date: March 15, 2004

By: /s/Ralph Ellison

Ralph Ellison
Chief Executive Officer and
President